SecBot SecBot
8-K ·Filed May 28, 2026

RPRX

Royalty Pharma plc
NEUTRAL
Impact 4/10
Horizonweeks Processed5mo ago SEC0001193125-26-245163
8-K material event: Items 1.01
Actionable Insight • Neutral

This is a routine refinancing that extends debt maturity by 5 years and maintains the same $1.8B commitment size. No financial data or guidance was reported. The covenant package is standard and the step-up for qualifying acquisitions signals flexibility for dealmaking. Monitor for any material acquisition announcements that could utilize the accordion feature or trigger the higher leverage limits.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$55.76
T+0 close · May 28, 2026 · via day close
Latest settled
+9.99%
T+60 · $61.33
Vs SPY
+8.81%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 29 $55.76entry
  2. T+1 · 6mo ago −1.04%α −1.32% · $55.18
  3. T+5 · 6mo ago −1.42%α −1.12% · $54.97
  4. T+20 · 5mo ago +2.39%α +4.18% · $57.09
  5. T+60 · 3mo ago +9.99%α +8.81% · $61.33
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Royalty Pharma entered into a new $1.8B unsecured revolving credit facility on May 22, 2026, replacing its prior credit agreement. The facility matures on May 22, 2031, and carries financial covenants including a maximum consolidated leverage ratio of 4.00x (stepping to 4.50x post-qualifying acquisition), a maximum portfolio cash flow ratio of 5.00x, and a minimum coverage ratio of 2.50x. This refinancing extends Royalty Pharma's debt maturity profile and maintains ample liquidity for acquisitions and working capital.

Key Financial Metrics

Deal Value
$1.8B
Deal Type
credit_facility

Key Facts

  • Royalty Pharma entered a $1.8B unsecured revolving credit facility on May 22, 2026.
  • The facility matures on May 22, 2031 (5-year term).
  • The agreement refinanced and replaced the prior $1.8B facility from September 2021.
  • Financial covenants include: max consolidated leverage ratio 4.00x (4.50x step-up for qualifying acquisitions), max portfolio cash flow ratio 5.00x (5.50x step-up), min coverage ratio 2.50x.
  • Initial pricing is at Level 2 (BBB/BBB/Baa2) with an applicable margin of 1.125% over Term SOFR and an unused commitment fee of 0.10%.
  • The facility includes an accordion feature allowing up to $900M in additional commitments.
  • L/C sublimit is $100M.
  • Proceeds can be used for working capital, acquisitions, and purchase of royalty assets.

Financial Impact

Refinancing of $1.8B revolving credit facility with a 5-year maturity, same size as prior facility. No new net debt created.

debt_maturityliquidityinterest_expense

Risk Factors

  • Leverage could increase if the company funds large acquisitions, though the step-up covenants provide buffer.
  • Uncertainty around future interest rates could impact borrowing costs on drawn amounts.
  • No financial performance data was provided in this filing to assess current credit metrics.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-245163
Document: d131735d8k.htm0001193125-26-245163
Document: 0001193125-26-245163-index-headers.html0001193125-26-245163
Document: 0001193125-26-245163-index.html0001193125-26-245163
Document: 0001193125-26-245163.txt0001193125-26-245163

Track record

23 reports on RPRX

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +15.20% at T+60 after the May 6, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 2/10 Entry price pending
  2. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $67.57 to $68.97 Now $68.53 +1.41% ▲ +2.07% −1.22% vs SPY
  3. Nov 4, 202612d ago 8-K Neutral 5/10 No price data
  4. Nov 4, 202612d ago Press Release Bullish 6/10 Entry $67.56 to $70.01 Now $68.53 +1.43% ▲ +3.63% +4.54% vs SPY
  5. Sep 30, 20266w ago Insider Cluster Bearish 5/10 Entry $57.63 to $56.21 Now $68.53 −18.91% ▲ +2.46% +3.77% vs SPY
  6. Sep 4, 202610w ago Press Release Bearish 5/10 Entry $60.59 to $58.47 Now $68.53 −13.10% ▲ +3.50% +2.38% vs SPY
  7. Aug 19, 202612w ago Insider Cluster Neutral 3/10 Entry $60.57 to $61.92 Now $68.53 +13.14% ▲ +2.24% +1.12% vs SPY
  8. Aug 12, 202613w ago 144 Neutral 3/10 Entry $58.56 to $60.58 Now $68.53 +17.02% ▲ +3.45% +5.41% vs SPY
  9. Aug 5, 202614w ago 8-K Bullish 6/10 Entry $57.75 to $59.22 Now $68.53 +18.66% ▲ +2.55% +2.19% vs SPY
  10. Jul 2, 202619w ago Insider Cluster Neutral 2/10 Entry $57.77 to $57.96 Now $68.53 +18.62% ▲ +0.33% −0.60% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens Wed (11h 41m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 28, 2026